Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer
NCT06437678
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Gastric Cancer
Interventions
DRUG:
Liposomal Irinotecan Hydrochloride
Sponsor
Zhejiang Cancer Hospital